| Project/Area Number |
26460052
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Physical pharmacy
|
|---|
| Research Institution | Kyoto Pharmaceutical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
草森 浩輔 京都薬科大学, 薬学部, 助教 (90707407)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 経皮吸収 / テリパラチド / マイクロニードル / 吸収改善 / 骨粗鬆症 |
|---|
| Outline of Final Research Achievements |
In this study, we prepared a self-dissolving microneedle arrays (MN) containing teriparatide (hPTH), a novel drug for the treatment of osteoporosis to improve the transdermal absorption of hPTH. In the release studies, the release of hPTH from MN was very rapid and almost 100% of drug was released from MN within 5 min. In addition, a rapid increase in the plasma concentration of hPTH was observed after the application of hPTH-MN to the skin. Furthermore,hPTH-MN has pharmacological effect for the treatment of osteoporosis in animal model. Finally, it was found that after the application of hPTH-MN to the skin, the transepidermal water loss (TEWL) value slightly increased, but was recovered to the control level, suggesting the safety of hPTH-MN. These findings indicated that the application of hPTH-MN to the skin is a very effective and safe administration method for the treatment of osteoporosis.
|
